Swiss biotech company Evolva closes series B round on CHF28m | AltAssets Private Equity News

Subscribe today

Advanced
Search

Swiss biotech company Evolva closes series B round on CHF28m

23 Oct 2009

Swiss biotech company Evolva has closed its series B funding round with CHF28m (€18.5m) in financing. Venture capital firm Aravis, an existing investor, led the round alongside new investors Auriga Partners, Vinci Capital - Renaissance PME and Wellington Partners.

Sorry, to read the full story you must be a Premium Subscriber

Are you a subscriber?

In order to view premium content you need to be a Premium Subscriber. You can subscribe now to access premium online content.

Become a Premium Subscriber
for only £150 / €180 / $225 p.a.

Login area

If you are already a AltAssets subscriber please log in below.